At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 145 enrolled
Drug / intervention
Brodalumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Bioequivalence Study Comparing a Single Subcutaneous Injection With a 1.5 mL Prefilled Syringe Versus 2 Subcutaneous Injections of 1 mL and 0.5 mL Prefilled Syringes of Brodalumab 140 mg/mL to Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Brodalumab for Psoriasis. Completed, enrolled 145 participants across 6 sites.
Detailed Summary
A healthy subject, 2-way cross-over study to evaluate the bioequivalence of a single dose of Brodalumab vs. two doses of Brodalumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartSep 2014
Primary CompletionNov 2014
Study CompletionDec 2014
TodayJul 2026
First PostedJun 25, 2014
Enrollment StartSep 1, 2014
Primary CompletionNov 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.0 years ago
Interventions
Brodalumabdrug
Brodalumab is a large molecule for the treatment of inflammatory diseases